Base Metals Investing BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
Base Metals Investing BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
Base Metals Investing Astria Therapeutics to Present at Upcoming CSACI 80th Anniversary Scientific Meeting
Base Metals Investing Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema
Base Metals Investing Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 - October 02, 2025
Base Metals Investing Astria Therapeutics Now Enrolling HAE Patients in the European Union for the Phase 3 ALPHA-ORBIT Trial
Base Metals Investing Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology
Base Metals Investing Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 - September 03, 2025
Base Metals Investing Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025
Base Metals Investing Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
